NCT07111546 2026-03-11
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
Clinical Trials
34 trialsNCT04999969 2026-02-03
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
AstraZeneca
Phase 2 Active not recruiting
NCT07229586 2025-12-19
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT05147272 2025-12-05
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Debiopharm International SA
Phase 1 Terminated
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT05279300 2025-08-11
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
Phase 1 Recruiting
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT03710876 2025-05-20
INFINITE
Ferring Ventures Limited
Phase 3 Active not recruiting
NCT02240238 2025-01-22
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NanoCarrier Co., Ltd.
Phase 1/2 Completed
NCT03421353 2024-08-21
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
AstraZeneca
Phase 1 Completed
NCT06446388 2024-06-06
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT04761601 2024-03-13
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
Phase 1 Terminated
NCT04934514 2024-02-20
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT00648648 2023-09-21
MK-1775-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05525247 2023-09-21
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Selecxine
Phase 1/2 Recruiting
NCT04481009 2022-12-12
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1/2 Completed
NCT02235688 2022-02-10
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed
NCT01063816 2021-08-02
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT04802980 2021-07-28
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Huabo Biopharm Co., Ltd.
Phase 1 Unknown
NCT02715531 2021-07-09
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02533674 2021-06-11
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT01862328 2020-06-22
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
Phase 1 Completed
NCT03920839 2020-04-24
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
Phase 1 Withdrawn
NCT02157792 2020-04-01
M6620 First in Human Study
EMD Serono
Phase 1 Completed
NCT01341457 2019-03-01
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT03503604 2018-04-20
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
Phase 1 Unknown
NCT00887757 2017-11-21
Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT01593228 2017-09-19
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Sanofi
Phase 3 Completed
NCT01125891 2017-06-23
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01359696 2017-04-12
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Genentech, Inc.
Phase 1 Completed
NCT01213381 2013-05-24
Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00459836 2011-03-02
PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors
Proacta, Incorporated
Phase 1 Completed
NCT00413686 2010-12-06
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT00061477 2007-01-26
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Eli Lilly and Company
Phase 2 Completed